drug development

Achaogen’s bankruptcy and going-out-of-business sale offer a grim cautionary tale for the future of antibiotic development
Achaogen’s bankruptcy and going-out-of-business sale offer a grim cautionary tale for the future of antibiotic development
Endpoints
Achaogen
bankruptcy
antibiotics
drug development
Flag link:
Drugs could mimic gut bacteria benefits to treat diabetes
Drugs could mimic gut bacteria benefits to treat diabetes
Pharmaforum
diabetes
drug development
microbiome
gut bacteria
Flag link:
1 Surprising Reason Alzheimer's Drugs Remain So Elusive
1 Surprising Reason Alzheimer's Drugs Remain So Elusive
Motley Fool
R&D
Alzheimer's disease
drug development
sleep science
Flag link:
Imbruvica resistance provides early but fertile development ground
Imbruvica resistance provides early but fertile development ground
EP Vantage
Arqule
Imbruvica
drug development
Btk inhibitors
Flag link:
J&J bags option on AdoRx lung cancer drugs
J&J bags option on AdoRx lung cancer drugs
Fierce Biotech
JNJ
AdoRx
lung cancer
drug development
Flag link:
130 medicines in development for asthma, allergies and other respiratory diseases
130 medicines in development for asthma, allergies and other respiratory diseases
PhRMA
allergies
asthma
respiratory disease
drug development
Flag link:
Biotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine?
Biotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine?
Pharmaforum
drug development
UK
Brexit
innovation
Flag link:
Case Study: How Shire improved its time-to-market
Case Study: How Shire improved its time-to-market
Pharmaforum
Shire
drug development
time-to-market
Flag link:
The 100 Leading Pioneers Of AI Drug Development
The 100 Leading Pioneers Of AI Drug Development
Forbes
drug development
artificial intelligence
Flag link:
Artificial Intelligence Gaining Ground in Drug Development
Artificial Intelligence Gaining Ground in Drug Development
BioSpace
CASP
machine learning
artificial intelligence
drug development
Merck
Takeda
Atomwise
Bayer
GSK
Google DeepMind
Recursion Pharmaceuticals
Flag link:
Argenx and Halozyme Ink Multiple Target Deal That Could Hit $540 Million
Argenx and Halozyme Ink Multiple Target Deal That Could Hit $540 Million
BioSpace
Argenx
Halozyme Therapeutics
drug delivery
drug development
Flag link:
‘We’re still waiting’: As cystic fibrosis drugs deliver new hope, not everyone is being swept up by scientific progress
‘We’re still waiting’: As cystic fibrosis drugs deliver new hope, not everyone is being swept up by scientific progress
Stat
cystic fibrosis
drug development
patients
Flag link:
Fintech And Biotech Are Coming Together To Transform Drug Development
Fintech And Biotech Are Coming Together To Transform Drug Development
Forbes
drug development
biotech
blockchain
financing
fintech
Flag link:
BridgeBio Pharma Raises $299.2 Million to Support Its Genetic Disease Development Programs
BridgeBio Pharma Raises $299.2 Million to Support Its Genetic Disease Development Programs
CP Wire
drug development
BridgeBio
genetic diseases
Flag link:
Developing Drugs Is an Expensive Process. How Do Biopharma Companies Hope to Change That?
Developing Drugs Is an Expensive Process. How Do Biopharma Companies Hope to Change That?
BioSpace
R&D
drug development
Flag link:
Lilly’s second immune-oncology candidate using Zymeworks’ Azymetric platform to start clinical trials
Lilly’s second immune-oncology candidate using Zymeworks’ Azymetric platform to start clinical trials
Pharmaceutical Business Review
Eli Lilly
Zymeworks
drug development
Azymetric platform
Flag link:
Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup
Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup
Bizjournals
Celgene
drug development
Kyn Therapautics
cancer
Flag link:
Sanofi expands multitargeting toolbox with Biomunex deal
Sanofi expands multitargeting toolbox with Biomunex deal
BioCentury
Sanofi
Biomunex Pharmaceuticals
drug development
Flag link:
The Demise Of A Once Promising Pancreatic Cancer Drug Is All Too Common
The Demise Of A Once Promising Pancreatic Cancer Drug Is All Too Common
Forbes
pancreatic cancer
drug development
Harvard
Flag link:
Partial Government Shutdown's Impact On FDA Drug Approvals
Partial Government Shutdown's Impact On FDA Drug Approvals
Forbes
FDA
drug approvals
drug development
government shutdown
Flag link:

Pages